Smart drug delivery systems to overcome drug resistance in cancer immunotherapy

作     者：Wenzhe Yi Dan Yan Dangge Wang Yaping Li Wenzhe Yi;Dan Yan;Dangge Wang;Yaping Li

作者机构：State Key Laboratory of Drug Research&Center of PharmaceuticsShanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China University of Chinese Academy of SciencesBeijing 100049China Department of PharmaceuticsSchool of PharmacyNanjing Medical UniversityNanjing 211116China Yantai Key Laboratory of Nanomedicine&Advanced PreparationsYantai Institute of Materia MedicaYantai 264000China Shandong Laboratory of Yantai Drug DiscoveryBohai Rim Advanced Research Institute for Drug DiscoveryYantai 264000China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2023年第20卷第4期

页      面：248-267页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Key R&D Program of China(Grant No.2022YFC3401404) the National Natural Science Foundation of China(Grant Nos.32170935 and 31930066) 

主　　题：Cancer immunotherapy drug resistance smart drug delivery system immunosuppressive microenvironment immune cell 

摘      要：Cancer immunotherapy,a therapeutic approach that inhibits tumors by activating or strengthening anti-tumor immunity,is currently an important clinical strategy for cancer treatment;however,tumors can develop drug resistance to immune surveillance,resulting in poor response rates and low therapeutic *** addition,changes in genes and signaling pathways in tumor cells prevent susceptibility to immunotherapeutic ***,tumors create an immunosuppressive microenvironment via immunosuppressive cells and secrete molecules that hinder immune cell and immune modulator infiltration or induce immune cell *** address these challenges,smart drug delivery systems(SDDSs)have been developed to overcome tumor cell resistance to immunomodulators,restore or boost immune cell activity,and magnify immune *** combat resistance to small molecules and monoclonal antibodies,SDDSs are used to co-deliver numerous therapeutic agents to tumor cells or immunosuppressive cells,thus increasing the drug concentration at the target site and improving ***,we discuss how SDDSs overcome drug resistance during cancer immunotherapy,with a focus on recent SDDS advances in thwarting drug resistance in immunotherapy by combining immunogenic cell death with immunotherapy and reversing the tumor immunosuppressive *** that modulate the interferon signaling pathway and improve the efficacy of cell therapies are also ***,we discuss potential future SDDS perspectives in overcoming drug resistance in cancer *** believe that this review will contribute to the rational design of SDDSs and development of novel techniques to overcome immunotherapy resistance.